JP2017522004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017522004A5 JP2017522004A5 JP2016568430A JP2016568430A JP2017522004A5 JP 2017522004 A5 JP2017522004 A5 JP 2017522004A5 JP 2016568430 A JP2016568430 A JP 2016568430A JP 2016568430 A JP2016568430 A JP 2016568430A JP 2017522004 A5 JP2017522004 A5 JP 2017522004A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antisense morpholino
- morpholino oligomer
- formula
- cpp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000692 anti-sense effect Effects 0.000 claims description 65
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 64
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims description 22
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims description 22
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 20
- 230000008685 targeting Effects 0.000 claims description 20
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 230000008238 biochemical pathway Effects 0.000 claims description 18
- 230000033077 cellular process Effects 0.000 claims description 18
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 14
- 230000003115 biocidal effect Effects 0.000 claims description 14
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 14
- -1 4-methoxytrityl Chemical group 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 229940113082 thymine Drugs 0.000 claims description 10
- 229940035893 uracil Drugs 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 9
- 125000005647 linker group Chemical group 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 7
- 125000003729 nucleotide group Chemical group 0.000 claims description 7
- MHCMWGPPLOSCJY-UHFFFAOYSA-N 4-$l^{1}-azanylmorpholine Chemical compound [N]N1CCOCC1 MHCMWGPPLOSCJY-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 13
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 241000589291 Acinetobacter Species 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 241000588722 Escherichia Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 241000588626 Acinetobacter baumannii Species 0.000 description 2
- 101710146995 Acyl carrier protein Proteins 0.000 description 2
- 108010003662 Chorismate synthase Proteins 0.000 description 2
- 108090000204 Dipeptidase 1 Proteins 0.000 description 2
- 102000002278 Ribosomal Proteins Human genes 0.000 description 2
- 108010000605 Ribosomal Proteins Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 102000006635 beta-lactamase Human genes 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101710135912 50S ribosomal protein L28 Proteins 0.000 description 1
- 241000023308 Acca Species 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 102100032534 Adenosine kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- 101000634117 Arabidopsis thaliana RNA polymerase sigma factor sigD, chloroplastic Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000007132 Carboxyl and Carbamoyl Transferases Human genes 0.000 description 1
- 108010072957 Carboxyl and Carbamoyl Transferases Proteins 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 108010085193 UDP-N-acetylglucosamine 1-carboxyvinyltransferase Proteins 0.000 description 1
- 101150023061 acpP gene Proteins 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229940041153 polymyxins Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462000431P | 2014-05-19 | 2014-05-19 | |
| US62/000,431 | 2014-05-19 | ||
| US201562129746P | 2015-03-06 | 2015-03-06 | |
| US62/129,746 | 2015-03-06 | ||
| PCT/US2015/031213 WO2015179249A1 (en) | 2014-05-19 | 2015-05-15 | Antisense antibacterial compounds and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017522004A JP2017522004A (ja) | 2017-08-10 |
| JP2017522004A5 true JP2017522004A5 (enExample) | 2018-06-21 |
| JP6687542B2 JP6687542B2 (ja) | 2020-04-22 |
Family
ID=54554572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016568430A Active JP6687542B2 (ja) | 2014-05-19 | 2015-05-15 | アンチセンス抗菌化合物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10391098B2 (enExample) |
| EP (2) | EP3146047A4 (enExample) |
| JP (1) | JP6687542B2 (enExample) |
| AU (1) | AU2015264449B2 (enExample) |
| CA (1) | CA2948568A1 (enExample) |
| WO (1) | WO2015179249A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0992230A3 (en) | 1998-10-08 | 2001-08-22 | KCI Licensing, Inc. | Medical pumping apparatus and related methods |
| AU2015258895A1 (en) | 2014-05-16 | 2016-11-24 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| AU2015264449B2 (en) | 2014-05-19 | 2022-05-05 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| WO2016108930A2 (en) | 2014-12-31 | 2016-07-07 | Geller Bruce L | Antisense antibacterial compounds and methods |
| EP3394261A4 (en) * | 2015-12-23 | 2019-11-27 | Oregon State University | ANTIBACTERIAL ANTISENSE COMPOUNDS AND METHOD |
| EP3394262B1 (en) | 2015-12-23 | 2024-08-28 | Oregon State University | Antisense antibacterial compounds and methods |
| EA201892467A1 (ru) * | 2016-04-29 | 2019-05-31 | Сарепта Терапьютикс, Инк. | Олигонуклеотидные аналоги, нацеленные на lmna человека |
| US20200283768A1 (en) * | 2017-10-23 | 2020-09-10 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| GB2579253A (en) | 2018-11-28 | 2020-06-17 | Pedanius Therapeutics Ltd | Antibacterial antisense agents |
| CN110885364B (zh) * | 2019-12-26 | 2021-02-02 | 江南大学 | 一种促进N-乙酰氨基葡萄糖生产的RamA转录因子突变体及其应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| EP0215942B1 (en) | 1985-03-15 | 1995-07-12 | Antivirals Inc. | Polynucleotide assay reagent and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| AU659482B2 (en) | 1991-06-28 | 1995-05-18 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| PT876165E (pt) | 1995-12-18 | 2006-10-31 | Angiotech Biomaterials Corp | Composicoes de polimeros reticulados e processos para a sua utilizacao |
| US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
| US20060241075A1 (en) | 2001-05-18 | 2006-10-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA) |
| US20040029129A1 (en) | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
| US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| WO2004093788A2 (en) | 2003-04-17 | 2004-11-04 | The Trustees Of Columbia University In The City Ofnew York | Desmoglein 4 is a novel gene involved in hair growth |
| US7468418B2 (en) | 2003-04-29 | 2008-12-23 | Avi Biopharma., Inc. | Compositions for enhancing transport of molecules into cells |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| AU2005327188C8 (en) | 2004-07-02 | 2011-09-22 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
| US20080125583A1 (en) | 2005-02-11 | 2008-05-29 | International Business Machines Corporation | Ribonucleic acid interference molecules |
| US7790694B2 (en) | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
| AU2006267051B2 (en) | 2005-07-13 | 2013-03-07 | Sarepta Therapeutics, Inc. | Antisense antibacterial method and compound |
| US8067571B2 (en) * | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US8143389B2 (en) | 2005-08-25 | 2012-03-27 | Texas Tech University | Inhibiton of metallo-β-lactamase by double-stranded DNA |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| ES2694726T3 (es) | 2007-06-29 | 2018-12-26 | Sarepta Therapeutics, Inc. | Conjugados peptídicos específicos de tejido y métodos |
| US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
| HRP20140646T1 (hr) | 2007-11-15 | 2014-09-26 | Sarepta Therapeutics, Inc. | Postupak sinteze morfolino oligomera |
| US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| US9914745B2 (en) | 2009-08-14 | 2018-03-13 | Indian Association For The Cultivation Of Science | Morpholino-based antisense agent |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| PT2623507T (pt) | 2010-09-30 | 2016-12-23 | Nippon Shinyaku Co Ltd | Derivado de ácido morfolino-nucleico |
| EP3067420A1 (en) | 2010-11-12 | 2016-09-14 | Sarepta Therapeutics, Inc. | Antisense antibacterial compounds and methods |
| US20120213663A1 (en) | 2011-02-23 | 2012-08-23 | King Fahd University Of Petroleum And Minerals | Method of removing e. coli bacteria from an aqueous solution |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| KR102183273B1 (ko) | 2011-05-05 | 2020-11-27 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
| KR101317263B1 (ko) | 2011-07-05 | 2013-10-10 | (주)지노첵 | 리얼타임 ｐｃｒ을 이용한 카바페넴 내성 장내균 검사 방법 및 키트 |
| WO2013011072A1 (en) | 2011-07-20 | 2013-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Carbapenemase and antibacterial treatment |
| AU2015258895A1 (en) | 2014-05-16 | 2016-11-24 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| AU2015264449B2 (en) | 2014-05-19 | 2022-05-05 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| WO2016108930A2 (en) | 2014-12-31 | 2016-07-07 | Geller Bruce L | Antisense antibacterial compounds and methods |
| EP3394261A4 (en) | 2015-12-23 | 2019-11-27 | Oregon State University | ANTIBACTERIAL ANTISENSE COMPOUNDS AND METHOD |
| EP3394262B1 (en) | 2015-12-23 | 2024-08-28 | Oregon State University | Antisense antibacterial compounds and methods |
-
2015
- 2015-05-15 AU AU2015264449A patent/AU2015264449B2/en active Active
- 2015-05-15 EP EP15795398.5A patent/EP3146047A4/en not_active Withdrawn
- 2015-05-15 JP JP2016568430A patent/JP6687542B2/ja active Active
- 2015-05-15 CA CA2948568A patent/CA2948568A1/en active Pending
- 2015-05-15 WO PCT/US2015/031213 patent/WO2015179249A1/en not_active Ceased
- 2015-05-15 US US14/714,104 patent/US10391098B2/en active Active
- 2015-05-15 EP EP19167404.3A patent/EP3569252B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017522004A5 (enExample) | ||
| JP2017522044A5 (enExample) | ||
| Sharma et al. | Versatility of peptide nucleic acids (PNA s): Role in chemical biology, drug discovery, and origins of life | |
| JP2017505623A5 (enExample) | ||
| US9315538B2 (en) | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity | |
| US8722874B2 (en) | Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity | |
| JP2016502858A5 (enExample) | ||
| EA015570B1 (ru) | Фармацевтическая композиция | |
| KR20220053048A (ko) | 안티센스 핵산 | |
| CN110234764B (zh) | 同时抑制mTOR基因及STAT3基因表达的核酸 | |
| CN110760516B (zh) | 核酸适配体衍生物和氨基化的核酸适配体衍生物以及它们的应用和药物偶合物 | |
| JP2018530530A5 (enExample) | ||
| JP2019500902A5 (enExample) | ||
| CN108779464A (zh) | 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病 | |
| JP2007510405A5 (enExample) | ||
| WO2019233921A1 (en) | Oligonucleotides for modulating atxn2 expression | |
| WO2017068790A1 (ja) | 核酸複合体 | |
| AU2014368776A1 (en) | Double-stranded polyC:poly(G/I) RNA for immunostimulation and cancer treatment | |
| WO2017068791A1 (ja) | 少なくとも１つのバルジ構造を有する核酸複合体 | |
| WO2020201339A1 (en) | Oligonucleotides for modulating atxn2 expression | |
| IL318474A (en) | Axon-skipping oligomer complexes for muscular dystrophy | |
| WO2020038973A1 (en) | Antisense oligonucleotides targeting sptlc1 | |
| EP3898975A2 (en) | Antisense oligonucleotides targeting card9 | |
| CN106906213B (zh) | 一种修饰的siRNA及其用途 | |
| KR20190087726A (ko) | mTOR 유전자 및 STAT3 유전자의 발현을 동시에 억제하는 핵산 |